SCHEMBL30074643

SCHEMBL30074643

NC(=O)c1ccc([18F])cn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.58
SIRT6 Q8N6T7 2/20 0.45
ADORA3 P0DMS8 1/20 0.42
TSHR P16473 1/20 0.42
MC4R P32245 1/20 0.42
ADRA1A P35348 1/20 0.42
MC3R P41968 1/20 0.42
NAMPT P43490 1/20 0.42
P4HTM Q9NXG6 3/20 0.41
APLNR P35414 1/20 0.41
KIT P10721 1/20 0.40
FLT3 P36888 1/20 0.40
LCK P06239 1/20 0.40
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
STAT3 P40763 1/20 0.39
JAK3 P52333 1/20 0.39
NNMT P40261 1/20 0.38
GRM2 Q14416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL319254 1.00 KMT2A (0.58) KMT2ASIRT6ADORA3TSHRMC4R
Hydrochloric Acid SCHEMBL4126365 0.98 KMT2A (0.56) KMT2ASIRT6ADORA3TSHRMC4R
Formic Acid SCHEMBL2588798 0.92 KMT2A (0.51) KMT2ASIRT6ADORA3TSHRMC4R
SCHEMBL25412159 0.92 KMT2A (0.51) KMT2ASIRT6ADORA3TSHRMC4R
Butyramide SCHEMBL27726780 0.85 KMT2A (0.45) KMT2ASIRT6TSHRNAMPTP4HTM
SCHEMBL25413661 0.85 KMT2A (0.45) KMT2ASIRT6NAMPTP4HTMJAK2
SCHEMBL27961477 0.84 KMT2A (0.51) KMT2AFLT3GRM2GSK3B
SCHEMBL110129 0.80 P4HTM (0.59) KMT2ATSHRP4HTMKDM4EALDH1A1
SCHEMBL17447442 0.80 P4HTM (0.42) KMT2AP4HTMAPLNRKDM4EALDH1A1
SCHEMBL30449388 0.80 P4HTM (0.59) KMT2ATSHRP4HTMKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11504439-B2 Radioactive compound for diagnosis of malignant melanoma and use thereof INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) 2022-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11504439-B2 Radioactive compound for diagnosis of malignant melanoma and use thereof MITF, BRAF, MEN1 KMT2A 1254/4885SIRT6 1910/4885ADORA3 1475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.